You have anything original to say, or are you just posting to...

First 3 Last

Share
Profile

Follow
onesurfed

2,073 Posts.

443

19/06/18

08:55

Post #: 33786015
Share

Originally posted by qqqqqqqqq ↑

The phase I study of Cantrixil commenced in December 2016 at five centres in the United States and Australia. It is designed in two parts: a dose escalation component (Part A), which seeks to understand the safety profile of the drug and to determine the maximum tolerated dose (MTD), and a dose expansion cohort (Part B), which seeks to explore initial signals of efficacy. Part A is expected to enroll between 3 and 42 patients, and Part B is expected to enroll 12 patients. The study is registered with clinicaltrials.gov as NCT02903771.
At the present time, the study has enrolled 10 patients in Part A. In general, the drug has encountered few dose-limiting toxicities and, as a result, most dosing cohorts have only required enrolment of a single patient, in line with the trial protocol, which has allowed the study to progress with a number of patients towards the lower extent of the forecast range.
Of the 10 patients recruited to date, 2 were withdrawn from the study prior to receiving treatment, generally on grounds of disease progression, reflecting the severity of this patient population. 3 of 5 patients evaluable for efficacy thus far have achieved ‘stable disease’ (SD) per RECIST criteria after 2 cycles of Cantrixil monotherapy. One patient demonstrated a ‘partial response’ (PR) after receiving Cantrixil in combination with chemotherapy. 3 patients have so far completed the full twenty-four weeks of dosing allowed for in the protocol.
The Data Monitoring Committee has recommended that additional patients should be enrolled to more fully understand the safety profile and to definitively determine the maximum tolerated dose, and the company has therefore continued Part A accordingly. It is now expected that Part A will conclude in the third calendar quarter of 2018, at which time Part B will commence. The Company expects to provide comprehensive data once Part A is complete.

Expand

You have anything original to say, or are you just posting to stir the pot? I'd say what I feel, but that would get me banned for another month.

KZA Price at posting: 61.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

ARV

Smallcap Artemis Res' jumps 23% on six digit gold grade rockchip find at Titan

Tonight's US CPI data could set the tone for November. What are markets expecting?

OCT

Octava Minerals joins the antimony train with high-grades on the radar at Yallagong, WA

IMA

Issues emerging as Australian companies tackle critical minerals challenge

ARB

Court process clears way for ARB to buy up 4 Wheel Parts business in the US